
CVRx (CVRX) Stock Forecast & Price Target
CVRx (CVRX) Analyst Ratings
Bulls say
CVRx Inc. demonstrated growth in its operational capabilities, with a total of 240 active implanting centers at the end of the quarter, reflecting an increase of 13 centers sequentially. The company's investments in expanding its infrastructure are underscored by a year-over-year rise of approximately 11% in selling, general, and administrative expenses, contributing to total operating expenses of $25.8 million, which increased by around 8% year-over-year. This expansion in implanting centers and strategic spending indicates a positive trajectory for the company as it seeks to enhance its market presence in the cardiovascular device sector.
Bears say
CVRx has revised its FY25 revenue guidance downward, adjusting the top end to a range of $55.0 - $57.0 million, reflecting a modest year-over-year growth of approximately 7-11%, which raises concerns about overall growth momentum. Furthermore, the company's gross margin for 2Q25 remained stagnant at 84%, suggesting ongoing challenges in improving profitability. Lastly, revenue estimates for 2026 have also been reduced to $67.6 million from a prior estimate of $74.1 million, indicating a potential slowdown in US market performance and overall financial prospects.
This aggregate rating is based on analysts' research of CVRx and is not a guaranteed prediction by Public.com or investment advice.
CVRx (CVRX) Analyst Forecast & Price Prediction
Start investing in CVRx (CVRX)
Order type
Buy in
Order amount
Est. shares
0 shares